Formulation and Evaluation of Melphalan Loaded Niosome for Cancer Treatment

Arul Packiadhas, Y (2021) Formulation and Evaluation of Melphalan Loaded Niosome for Cancer Treatment. Masters thesis, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore.


Download (2MB) | Preview


The concept of incorporating the drug into liposomes or niosomes is for better targeting the drug at appropriate tissue destination. It is widely accepted by the researchers and academicians. Niosomes represent as promising drug delivery system. Niosomes presents a structure similar to liposomes and hence they can they can represent alternative vesicular system with representative to liposomes. Niosomes thought to be better candidate for drug delivery as compared with liposome due to various factor like cost, stability and etc. Melphalan is an anti-neoplastic drug in the class of alkylating agent used to treat various forms of cancer. The main disadvantage of using melphalan as an anti-cancer drug is as it commonly affects normal cells. There is a correlation between the conventional drug delivery system and cell damage. so, the Targeted drug delivery system may modify this correlation by controlling the cell damage by using novel carriers. The novel delivery system of melphalan is to decrease the normal cell death and also increase the cell death of cancer cells. In this work we prepared different niosomal formulations containing melphalan, span 60 and cholesterol by using probe sonication method. Chemical compatibility study confirmed that there is no interaction between melphalan (drug) and span60 & cholesterol (excipients) before the formulation. The pH of all prepared formulations was found to be excellent. Particle size was much affected by the drug and polymer ratio. The surface morphology and shape of the different formulated noisome were observed from a transmitted electron microscope. They are spherical and entrapped numerous drug particles and can be assigned for better targeting. Entrapment efficiency for different niosomal formulations were calculated and it was found that the F1 formulation had the highest entrapment of 97.12 % and the lowest entrapment of 88.06 % was found from formulation F3. The Zeta potential of the formulation F2 had the highest value of -14.4 and the formulation F1 had lowest value of -0.29. No charge inducing agents were added to these formulations and thus the potential value is low. In-vitro drug release data was studied by using dialysis method for all the prepared niosomal formulations and from this study, it was found that formulation F1 had the maximum percentage release of 96.10 % at the end of the 24th hour. The drug release kinetics for all the prepared niosomal formulations were studied by computational modelling method from this study it was found that F1 formulation followed Hixon with R2 values 0.9877, F2 formulation followed Higuchi with R2 values 0.9553 and F3 formulation followed First order with R2 values 0.9723 respectively. FUTURE SCOPE: The result of the present research work provides useful information for future studies aiming at develop products, especially noisome in large scale production. The noisome delivery approach design is more advantageous than available conventional dosage form by avoiding systemic side effects and reducing the frequency of the drug administration because of using novel carrier.

Item Type: Thesis (Masters)
Additional Information: 261910153
Uncontrolled Keywords: Formulation, Evaluation, Melphalan, Niosome, Cancer Treatment.
Subjects: PHARMACY > Pharmaceutics
Depositing User: Subramani R
Date Deposited: 01 Nov 2022 03:26
Last Modified: 01 Nov 2022 03:26

Actions (login required)

View Item View Item